The present invention relates to a method for monitoring kinase activity or activation in a sample, the method comprises the steps of a) providing a sample comprising a kinase, b) incubating the sample with a protease to cleave the kinase provided in step a) into protease specific proteolytic peptides, c) applying phosphopeptide enrichment to the sample, d) analysing the sample obtained in step c) via liquid chromatography-mass spectrometry, and e) detecting phosphorylations of the kinase provided in step a), wherein the detection of step e) is performed only in case a proteolytic peptide associated with the activation region of the kinase is identified.

The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.

A hybridoma cell stain and a monoclonal antibody secreted therefrom and application thereof belong to the technical field of prevention and treatment of Trichinella spiralis (T. spiralis). Aiming at the technical problem of how to specifically diagnose trichinellosis, the disclosure provides a hybridoma cell strain deposited under an accession number of CGMCC No. 18317. Tests show that the monoclonal antibody Ts-ZH68-2A4-Ab secreted by the hybridoma cell strain can compete with the positive serum of pigs infected with T. spiralis for binding to Ts-ZH68 antigen, and the recognition peptide is .sup.222GVDRSATCQGDSGGP.sup.236. The monoclonal antibody of the disclosure and the Ts-ZH68 protein B cell epitope polypeptide recognized by the monoclonal antibody can be used to prepare a reagent or a vaccine for diagnosing or preventing infection of T. spiralis, laying the foundation for establishment of a serological diagnosis method of T. spiralis.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

The present invention is related to a novel and direct method for measuring the fibrinogen level in a sample, which is particularly useful in emergency situations. The novel method is independent of thrombin formation and is not interfered by the presence of oral anti-coagulation drugs or other chemicals contrary to the commonly used clotting assays.

The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.

The present application provides compositions and methods for determining a disease or condition in a subject. The method comprises contacting a body fluid with a molecule comprising a reporter thereof and the reported is cleaved by an agent in the body fluid. Diseases and conditions that can be determined by the method are also described.

This invention discloses a pretreatment approach for blood and bodily fluids to remove unwanted protein interferences in the measurement of analytes. Enzymes either contained in a cartridge or immobilized on a solid support break down proteins that complex with the analyte to shield it from detection. This pretreatment significantly enhances the detectability of analytes and does not require subsequent clean-up steps that would normally be required to ensure the functionality of the analysis method, thereby, creating a simple yet powerful approach for sample pretreatment in a variety of settings ranging from a complex laboratory infrastructure to a field deployable application.

The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.